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ABSTRACT 25 
This study aimed to develop and characterize stable films as potential protein delivery dressings 26 
to wounds. Films were prepared from aqueous gels of sodium alginate (SA) and glycerol 27 
(GLY) (SA:GLY 1:0, 1:1, 1:2, 2:3, 2:1, 4:3) , . Purified recombinant glutathione-s-transferase 28 
(GST), green fluorescent protein (GFP) and GST fused in frame to GFP (GST-GFP) (model 29 
proteins) were characterized (SDS PAGE, Western blotting, immune-detection, and high 30 
sensitivity differential scanning calorimetry) and loaded (3.3, 6.6 and 30.2 mg/g of film) into 31 
SA:GLY 1:2 film. These were characterized using texture analysis, differential scanning 32 
calorimetry (DSC), thermogravimetric analysis (TGA), scanning electron microscopy, 33 
swelling, adhesion, dissolution and circular dichroism (CD). The protein loaded dressings were 34 
uniform, with a good balance between flexibility and toughness. The films showed ideal 35 
moisture content required for protein conformation (TGA), interactions between proteins and 36 
film components (DSC), indicating stability which was confirmed by CD. Swelling and 37 
adhesion showed that formulations containing 6.6mg/g of protein possessed ideal 38 
characteristics and used for in vitro dissolution studies. Protein release was rapid initially and 39 
sustained over 72 hours and data fitted to various kinetic equations showed release followed 40 
zero-order and Fickian diffusion. The results demonstrate the potential of SA dressings for 41 
delivering therapeutic proteins to wounds 42 
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1. Introduction 53 
A wound is defined as a disruption of normal anatomic structure and physiology [1] of a tissue 54 
and represents damage of natural defense barriers which encourages invasion by 55 
microorganisms [2]. The process of wound regeneration is a complex combination of matrix 56 
destruction and reorganization [3] which requires well-orchestrated processes that lead to the 57 
repair of injured tissues [4]. These processes are integrations of complex biological and 58 
molecular events culminating in cell migration, proliferation, extracellular matrix deposition 59 
and the remodeling of scar tissues [5]. This process is driven by numerous cellular mediators 60 
including cytokines, nitric oxide, and various growth factors [6] (most of them proteins) which 61 
stimulate cell division, migration, differentiation, protein expression and enzyme production. 62 
Their wound healing properties are mediated through the stimulation of angiogenesis and 63 
cellular proliferation [7] which affects the production and degradation of the extracellular 64 
matrix and also plays a role in cell inflammation and fibroblast activity [8]. The field of biologic 65 
wound products aims to accelerate healing by augmenting or modulating these inflammatory 66 
mediators. These products have experienced remarkable growth as our understanding of the 67 
wound healing response has increased [6], coupled with the large number of recombinant 68 
proteins being investigated for therapeutic applications.  69 
 70 
Alginate dressings are bioactive formulations composed of a polysaccharide polymer called 71 
alginic acid which contains guluronic and mannuronic acid units [9]. These dressings can occur 72 
in the form of fibers rich in mannuronic acid (e.g. SorbsanTM) which form flexible gels upon 73 
hydration or those rich in guluronic acid residues which form firmer gels upon exudate 74 
absorption (e.g. KaltostatTM). Alginate dressings are non-toxic and aid in hemostasis as part of 75 
the wound healing process [10-13]. In addition, they activate human macrophages to produce 76 
tumor necrosis factor-Į71)ĮZKLFKLQLWLates inflammatory signals [14].  77 
The therapeutic effects of large macromolecules such as proteins and growth factors 78 
are limited by their low bioavailability and poor stability, whilst multiple injections can result 79 
in poor patient compliance. Therefore, drug delivery systems such as adhesive film dressings 80 
present a valid approach to overcome these limitations since films are simple, easy to prepare 81 
and characterizH)XUWKHUEHLQJ LQ WKHGU\VWDWH LW¶Veasy to incorporate and stabilize labile 82 
proteins without the need for more expensive drying approaches such as freeze-drying, 83 
however, this depends on the type of protein and the temperature of drying. It has been 84 
proposed that films have potential to be used to deliver genetic and protein based molecules to 85 
wound sites [15]. Alginate film dressings are easily biodegradable and painlessly removed via 86 
saline irrigation when trapped in the wound thus preventing damage to newly formed 87 
granulation tissue [16, 17].  88 
 89 
The requirement of wound management products with ideal characteristics has necessitated the 90 
need for advanced formulations such as alginate having improved physico-mechanical 91 
properties and general functional performance such as bioadhesion, but which are also able to 92 
actively take part in the wound healing process [2, 18]. In this study, we report on the use of 93 
film dressings formulated from two readily biodegradable materials; SA (film forming 94 
polymer) and GLY (plasticizer), loaded with recombinant proteins (GST, GFP and GST-GFP) 95 
as model protein drugs for potential wound healing. Films were prepared from aqueous gels of 96 
SA by solvent casting and characterized for functional characteristics expected for wound 97 
dressings. 98 
 99 
2. Experimental 100 
2.1 Materials 101 
Nitrocellulose membrane, thiazolyl blue tetrazolium bromide, polyethyleneimine (branched, 102 
Mn 60000), dextran (Mw 35000-45000), iVRSURS\Oȕ-D-1-thiogalactopyranoside (IPTG), L-103 
glutathione, guanidine hydrochloride, MTT reagent [3-(4,5-dimethylthiazol-2-yl)-2,5-104 
diphenyltetrazolium bromide] were obtained from Sigma (Gillingham, UK). Tryptone was 105 
obtained from Oxoid, (Hampshire, UK). Yeast extract, dimethyl sulfoxide (DMSO), 106 
trismethylamine and sodium chloride were obtained from Fisher Scientific, (Leicestershire, 107 
UK). Glutathione sepharose 4B, ECL Western blotting detector reagents 1 and 2 were obtained 108 
from GE HealthCare, (Buckinghamshire, UK). Acrylamide/Bis 37.5:1 and Bradford reagent 109 
(1x) were obtained from Bio-Rad, (Hempstead, UK). Anti-rabbit immunoglobulin (IgG)-110 
Horseradish peroxidase (HRP) conjugated and GFP were obtained from Invitrogen, (Paisley, 111 
UK). Anti-Rabbit IgG-HRP and GST were obtained from Abcam, (Cambridge, UK). 112 
Recombinant GST-GFP, GST and GFP were prepared in house (Richardson lab, University of 113 
Greenwich, UK). Sodium alginate [PHGLXPYLVFRVLW\000 cps) grade; M/G ratio of 1.56], 114 
glycerol and bovine serum albumin were all obtained from Sigma-Aldrich, (Gillingham, UK). 115 
'XOEHFFR¶V-PRGLILHGHDJOH¶Vmedium (D-MEM), PBS, penicillin, streptomycin and glutamine 116 
were all obtained from Gibco, (Paisley, UK). Gelatin was obtained from Fluka Analytical, 117 
(Steinheim, Germany) and calcium chloride from Sigma Aldrich, (Steinheim, Germany).  118 
 119 
2.2 Recombinant protein preparation, purification and characterization  120 
The protein production, purification, immuno-detection and characterization were performed 121 
according to that previously reported [19, 20]. The eluted proteins (GST-GFP, GST and GFP) 122 
were sealed in cellulose acetate dialysis membrane and dialyzed against 4L of cold 1x PBS 123 
(4°C) overnight and changing the dialysis buffer every 2 hours afterwards with a minimum of 124 
4 changes of  (1x) PBS. 15µL each of purified proteins [GST-GFP (5µg), GST (2mg) and GFP 125 
(1mg)] and controls [Spectra Multicolor broad range protein molecular weight ladder 126 
(Fermentas, Cambridgeshire, UK) and bovine serum albumin (BSA) standards (75µg)] were 127 
loaded onto sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) apparatus 128 
using 6M guanidine containing Laemmli buffer and 10% (v/v) beta-mercaptoethanol (BME), 129 
with a running bufIHU [ DV SHU PDQXIDFWXUHU¶V LQVWUXFWLRQV 7KH ORDGHG VDPSOHV ZHUH130 
resolved by applying 100V of direct current for 80 minutes. The gel was then stained with 131 
Coomassie brilliant blue for 2 hours and de-stained with Coomassie de-staining solution for 132 
another 2 hours, further soaked in 5% (v/v) glycerol / PBS and dried overnight using a gel 133 
drying kit (Promega, Hampshire, UK). Western blotting and immuno-detection was used to 134 
detect GFP-GST after separation and its immobilization on a solid phase-support. The 135 
H[SHULPHQW ZDV SHUIRUPHG LQ DFFRUGDQFH ZLWK WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV DQG DV136 
previously reported [19]. The specific protein bands were identified by superimposing the 137 
developed X-ray film onto the membrane in the cassette.  138 
 139 
2.3 Preparation of film dressings 140 
Various sodium alginate (SA) gels (1% w/w) with and without plasticizer (GLY) were 141 
employed to determine the best SA:GLY ratio (SA:GLY ± 1:0, 1:1, 1:2, 2:3, 2:1, 4:3) for the 142 
preparation of uniform and homogeneous films. Drug loading was achieved by formulating the 143 
selected optimized film prepared above, with increasing drug concentrations (3.3, 6.6 and 144 
30.2mg/g of film) for all three proteins. SA was added gently and in small quantities (so as to 145 
avoid formation of lumps) to warm PBS (45°C) in a beaker and magnetically stirred until SA 146 
was completely dissolved (2 hours) to yield a clear homogeneous gel. The required amount of 147 
GLY was added to the gels with continuous stirring and heating for a further 1 hour. The model 148 
proteins were added to the optimized gel with gentle stirring and heating (45°C) until a 149 
homogenous mix was obtained (1 hour) and allowed to stand for 5 minutes (to remove air 150 
bubbles). 30g was poured into Petri dishes (90mm diameter) and placed in a vacuum oven at 151 
40°C for 18 hours.  152 
 153 
2.4 MTT cytotoxicity assay 154 
MTT assay was used to evaluate the cytotoxicity of the proteins and SA using dextran (Mw 155 
35,000-45,000) and polyethyleneimine PEI (branched, Mn ~ 60,000), as negative and positive 156 
controls respectively. Adherent Vero cells (1x104 cells/well) were used to seed a sterile, flat-157 
bottom 96-well tissue culture plate containing 'XOEHFFR¶VPRGLILHGHDJOHVPHGLXP(D-MEM) 158 
plus 10% (v/v) PBS, penicillin (100U/mL), streptomycin (100µg/mL) and glutamine 159 
(292µg/mL) (all under sterile conditions in a laminar hood) and incubated at 37°C in 5% (v/v) 160 
CO2 for 24 hours. After 24 hours, the cells were exposed to either PEI, dextran, GST-GFP, 161 
GST and GFP (0-3mg/mL) in cell culture medium and incubated for 68 hours. 10µL (50µg) of 162 
MTT from stock solution (5mg/mL) was added to each well and the plate incubated for a further 163 
4 hours bringing the total incubation time to 72 hours. The contents of the plate were decanted 164 
and 100µL of DMSO was added to each well, incubated at room temperature for 30 minutes 165 
and the absorbance read on a Multi-scan EX Micro-plate photometer (Thermo Scientific, 166 
Essex, UK) at optical density (OD) 540nm. For SA however, adherent cells (Vero, 1x 104) 167 
were exposed to SA gel after 24 hours. Data obtained was expressed as percentage cell viability 168 
(mean ± standard deviation of the mean). 169 
 170 
2.5 Thermal analysis 171 
2.5.1 High sensitivity differential scanning calorimetry (HSDSC) 172 
Preliminary characterization of the three model proteins were investigated using HSDSC 173 
determining the effect of pH (6.0, 7.5, 8.0 and 10.0), scan rate (0.5, 1.0 and 2.0°C/minute), 174 
protein concentrations (1.0, 2.5 and 5.0mg/mL) and reversibility. Degassed buffer and protein 175 
solutions (800µL) were loaded into the reference and sample capillary cells using a calibrated 176 
automatic pipette. The cells were covered using rubber caps on same sides. The entire cell 177 
chamber was then tightly covered with the chamber lid to maintain constant pressure and 178 
samples analyzed with a pressure of 3 atmospheres, equilibration for 600 seconds and heating 179 
from 10°C to 95°C at the scan rates above. Prior to sample analyses (both water and buffer 180 
scans were run using the same parameters described above for analyzing the samples and 181 
showed a flat baseline which was used as reference scans before analyzing the samples. 182 
 183 
2.5.2 Differential scanning calorimetry (DSC) 184 
Before analyzing of the samples, the DSC instrument was calibrated.  Two different 185 
calibration experiments of the DSC machine (Q2000 TA instrument. The first experiment 186 
was performed in two stages i.e. determination of the cell resistance and capacitance. The 187 
determination of the cell resistance was performed with an empty cell. During this 188 
experiment, the cell was equilibrated at -90°C and held at this temperature (isothermal) for 5 189 
minutes, followed by a heating ramp from -90 to 400°C at a rate of 20°C/min. The 190 
determination of the cell capacitance, involved a similar experimental procedure as the cell 191 
resistance but sapphire discs of known weight and heat capacity were placed on the reference 192 
and sample cells. The second calibration experiment involved the determination of the cell 193 
constant and temperature calibration, which were obtained from a single experiment. In this 194 
experiment 1-5 mg of indium standard was pre-heated to which is above its melting transition 195 
temperature and held isothermally (5 minutes). The sample was then cooled to 100°C, held 196 
isothermally for a further 5 minutes and subjected to a heating ramp (10ºC/min) to a 197 
temperature above the melting transition. The enthalpy of fusion was determined by 198 
integration and compared with the known value (28.71 J/g). The cell constant was calculated 199 
as the ratio between the experimentally determined and expected value and expected to be 200 
between 1 and 1.2.  The melting temperature was determined using the extrapolated onset 201 
value, and this was also compared with the known value (56.6°C) and the difference 202 
calculated for temperature accuracy.  203 
 204 
DSC analysis was carried out on the starting materials (SA, GLY, GST, GFP and recombinant 205 
GST-GFP), formulated gels, as well as blank (non-protein) and protein loaded films. About 206 
19.0-20.0mg of GLY and gels, 3.3-8.0mg of SA, blank and protein loaded films were loaded 207 
into tarred Tzero aluminium pans which were crimped and hermetically sealed with one pin 208 
hole on the lid using a Tzero sample press (TA instruments, Crawley, UK). The analysis was 209 
performed using a Q2000 calorimeter (TA Instruments, UK), under inert nitrogen (N2) gas at 210 
a flow rate 50mL/minute, equilibration at -90°C, isothermal for 5 minutes and finally dynamic 211 
heating to 400°C at a heating rate of 10°C/minute.  212 
 213 
2.5.3 Thermogravimetric analysis (TGA) 214 
Tests were carried out on the starting materials [(SA, GLY), recombinant GST-GFP, GST and 215 
GFP (proteins) and the blank and protein loaded films. Analysis was carried out using a Q5000-216 
IR TGA instrument (TA Instruments, Crawley, UK) by loading about 8.0 - 10.0mg (SA, GLY), 217 
9.5-10.0mg (proteins) and 3.0-3.6mg (film). The analysis was performed under inert nitrogen 218 
(N2) gas at a flow rate of 50mL/minute and dynamic heating from ambient (~25°C) to 600°C 219 
at a heating rate of 10°C/minute.  220 
 221 
2.6 Tensile characterization  222 
The tensile properties of the films (thickness, 0.1mm) were evaluated using a TA HD Plus 223 
(Stable Micro Systems Ltd, Surrey, UK) texture analyzer equipped with a 5kg load cell and a 224 
Texture Exponent-32® software program. The films (n=3), free of any physical defects (cracks 225 
or tears) were cut into dumb-bell shapes and stretched between two tensile grips at a speed of 226 
6mm/s using a trigger force of 0.1N until films broke. The distance between the grips was 3mm 227 
whilst the width of the films was 1mm. Testing was first carried out on the blank (non-protein 228 
loaded) films with different plasticizer concentrations (SA:GLY, 1:0, 1:1, 1:2, 2:3, 2:1, 4:3) to 229 
determine the film with optimum mechanical (tensile) properties [15] for protein loading. 230 
Further to this, tests were carried out on protein loaded films. The tensile strength (brittleness), 231 
<RXQJ¶VPRGXOXVULJLGLW\VWLIIQHVVDQGHORngation (elasticity and flexibility) at break were 232 
determined from the force-time profiles using equations 1, 2 and 3.  233 
 234  ቀ ୒୫୫మቁ ൌ  ሺ୊୭୰ୡୣୟ୲ୠ୰ୣୟ୩ሺ୒ሻሻ୍୬୧୲୧ୟ୪ୡ୰୭ୱୱୱୣୡ୲୧୭୬ୟ୪ୟ୰ୣୟሺ୫୫మሻ                  Equation 1 235 
 236 ሺሻ ൌ  ୗ୪୭୮ୣ୍୬୧୲୧ୟ୪ୡ୰୭ୱୱୱୣୡ୲୧୭୬ୟ୪ୟ୰ୣୟሺ୫୫మሻ௫௖௥௢௦௦ି୦ୣୟୢୱ୮ୣୣୢሺౣ౩ౣ ሻ  Equation 2 237 
 238 ሺ ?ሻ ൌ ୧୬ୡ୰ୣୟୱୣ୧୬୪ୣ୬୥୲୦ሺ୫୫ሻୟ୲ୠ୰ୣୟ୩୧୬୧୲୧ୟ୪୤୧୪୫୪ୣ୬୥୲୦ሺ୫୫ሻ ൈ  ? ? ?                     Equation 3 239 
 240 
2.7 Scanning electron microscopy (SEM) 241 
This was used to evaluate the surface morphology and topography of the films with and without 242 
proteins. Films were cut into rectangular (3x5mm) pieces and placed on the exposed side of a 243 
double-sided carbon adhesive tape stuck onto aluminum stubs (Agar Scientific, Essex, UK). 244 
Images were acquired using a Hitachi SU 8030 FEG-SEM (Hitachi High-Technologies, Tokyo, 245 
Japan) by generating secondary electrons at an accelerating voltage of 2kV and working 246 
distance of 15mm and magnification of x50. 247 
 248 
2.8 Hydration and swelling 249 
The swelling capacity of the formulated blank and protein loaded films were determined in 250 
simulated wound fluid (SWF) containing 0.02M calcium chloride, 0.4M sodium chloride, 251 
0.08M tris-methylamine and 2% (w/v) bovine serum albumin in deionized water [2]. The pH 252 
was adjusted to 7.5 using 2M HCl, mimicking chronic wound with pH reported to be in the 253 
range of 7.2 to 8.9 [21]. Films were cut into 2x2 cm strips, weighed and immersed in SWF 254 
(10mL). The weight change of the hydrated films was determined every 15 minutes for 120 255 
minutes. Hydrated films (n = 3) were blotted carefully with filter paper to removes excess SWF 256 
on the surface and reweighed immediately on an electronic balance. The percentage swelling 257 
index (%Is) was calculated from equation 4. 258 
%Is = (Ws-Wd)/Wd x 100   (Equation 4) 259 
Where Ws is the weight of films after hydration and Wd is the weight of films before hydration. 260 
 261 
2.9 In vitro wound adhesion 262 
In vitro wound adhesion test was carried out on the blank and protein loaded films using a 263 
TA HD plus Texture Analyzer (Stable Micro System, Surrey, UK) fitted with a 5kg load cell 264 
in tension mode. Films (n=4) were cut to square strips (2x2cm) and attached to a 75mm 265 
diameter probe using a double sided adhesive tape. Prior to testing, 20g of 6.67% (w/v) gelatin 266 
was poured into a Petri dish (90mm in diameter) and allowed to set at 4°C RYHUQLJKWȝ/RI267 
SWF (pH 7.5) was spread evenly using an agar plate spreader so as to simulate a wound 268 
surface2. The films were kept in contact with the gelatin solution for 1 minute before 269 
detachment. The probe was set at a pre-test speed of 0.5mm/s, test speed of 0.5mm/s, a post-270 
test speed of 1mm/s, and an applied force of 1N. The peak adhesive force (PAF) representing 271 
maximum force required to separate the films from the simulated wound surface, the area under 272 
the curve (AUC) representing the total work of adhesion (TWA) and the cohesiveness 273 
representing the distance travelled (mm) before detaching from the simulated wound surface 274 
were determined.  275 
 276 
2.10 In vitro protein dissolution and release studies 277 
The in vitro protein dissolution and release studies were carried out as previously described 278 
[22]. A modified Franz diffusion cell with a wire mesh washed by 8mL SWF (pH 7.5, 37°C) 279 
was used to simulate the natural wound environment. The protein (6.6mg/g) loaded film 280 
dressings (50mg, n=4) were placed on the wire mesh. Aliquots (ȝ/) of SWF was withdrawn 281 
at regular intervals and analyzed using Bradford assay and replaced with same volume of fresh 282 
SWF (pH 7.5) to maintain a constant volume and sink conditions. The absorbance of the 283 
sampled aliquot was measured using a Multi-scan EX Micro-plate photometer (Thermo 284 
Scientific, Essex, UK) at 595nm and 450nm and the ratio of the absorbance values determined 285 
(from linearization of the curve as described in [23, 24]. The cumulative percentage (%) drug 286 
release was plotted against time and the proteins release kinetics determined by finding the best 287 
fit of the % release against time data to Higuchi (equation 5), Korsmeyer-Peppas (equation 6), 288 
zero order (equation 7) and first order (equation 8) equations.  289 
 290 
Qt = kHt1/2         Equation 5 291 
Qt is the amount of drug released at time (t), kH is the (Higuchian) release rate constant. 292 
 293 
Ɛn(Qt / Q) = ƐnNQƐnt        Equation 6 294 
Qt is the amount of drug released at a given time (t), Qis the amount of drug present initially, 295 
k is a constant involving the geometry and structural characteristics of the film and n release 296 
exponent. 297 
 298 
Qt ± Q0 = k0t                 Equation 7 299 
Qt is the amount of drug released in time (t), Q0 is the amount of drug dissolved at time zero 300 
and k0 is the zero-order release rate constant.    301 
 302 
 Ɛn (Q/ Q1) = k1t                 Equation 8 303 
Qis the initial total amount of drug present, Q1 is the amount of remaining drug at time (t) and 304 
k1 is the first order release rate constant. 305 
 306 
2.11 Far-UV circular dichroism spectroscopy 307 
The conformational (secondary) structures of the pure model proteins (GST-GFP, GST and 308 
GFP) and released protein from the films dressings were examined in the far-UV region of a 309 
circular dichroism (CD) instrument; wavelength range (190±260nm), band width (1nm), path 310 
length (0.01cm) and 10 seconds time per point, in 0.01M PBS (pH 7.5) at 20°C using a 311 
Chirascan CD spectrometer (Chirascan, Applied Photophysics, UK). 312 
 313 
2.12 Statistical analysis 314 
The various formulations and experimental variables used to characterize the films were 315 
compared by statistical data evaluation (Microsoft Excel, Office 2013 software) using a two 316 
tailed student t-test at 95% confidence interval (p-value < 0.05) as the minimal level of 317 
significance. 318 
 319 
 320 
3 Results  321 
3.1. Protein characterization  322 
The molecular weights of the proteins observed on the gel were 52kDa, 27kDa and 28kDa 323 
confirming the proteins of interest i.e. GST-GFP, GFP and GST (pGEX3x and pGEX5x) 324 
respectively. The molecular weights observed from immune-blotting: GFP (27 kDa), GST (28 325 
kDa) and GST-GFP (52kDa), shown in Fig. 1a, 1b and 1c respectively, correspond to that 326 
reported in the literature [19] and confirmed the Coomassie observations.  327 
 328 
3.2 MTT cytotoxicity assay 329 
Fig. 2 shows the toxicity profile for dextran and PEI, GST-GFP, GST, GFP and SA respectively 330 
(n = 6). The results showed 5-10% cell viability for PEI with cell death at 72 hours and 100% 331 
cell viability for dextran as was expected. Almost 100% cell viability was observed for GST-332 
GFP, GST, GFP and SA after 72 hours, with negligible cell death noticed and therefore, all 333 
three proteins and SA were confirmed as non-toxic. The results (Fig. 2F) show a clear profile 334 
of the cytotoxicity of SA on adherent epithelial mammalian cells (Vero (ATCC® CCL-81TM) 335 
confirming that SA is non-toxic under the conditions tested. This is not surprising since SA is 336 
approved for oral formulations and moist wound dressings and therefore the results here 337 
confirm its safety for use as a protein delivery dressing for wound healing.  338 
 339 
3.3 Thermal analysis 340 
3.3.1 High sensitivity differential scanning calorimetry (HSDSC) 341 
Table 1 shows the HSDSC profiles of the three proteins obtained by varying three main 342 
experimental conditions (scan rate, pH and concentration). Detailed description of the results 343 
showing the effect of the three experimental variables on the HSDSC profiles are provided as 344 
supplementary data in appendix A1.  345 
3.3.2 Differential scanning calorimetry (DSC) 346 
All three proteins showed similar characteristics as observed in their thermograms (Fig. 3A).  347 
Detailed descriptions of the DSC results for the pure proteins are given in appendix A2. GLY 348 
showed two endothermic peaks at 136.54°C and 293.67°C attributed to water loss and boiling 349 
(Fig. 3B) whilst SA showed one endothermic peak at 109.23°C and an exothermic peak at 350 
242.59°C (Fig. 3C) that can be attributed to dehydration and thermal degradation of 351 
intermolecular side chains respectively [26, 27]. Differences were observed between the DSC 352 
thermograms of the blank and protein loaded films (Fig. 3D) which could be an indication of 353 
interaction between the polymer and proteins. The blank film was characterized by two 354 
endothermic transitions at 98.61°C and 250.05°C (Fig. 3D). However, the protein loaded films 355 
showed four endothermic transitions with multiple stages of polymer degradation with the 356 
exception of GST (30.2, 3.3mg/g) and GST-GFP (30.2mg/g) respectively, which showed two 357 
endothermic transitions (Fig. 3D). The high dehydration temperatures seen in both blank and 358 
protein loaded films with endset peak at 126.32°C can be attributed to bound water molecules 359 
within the polymeric film allowing for more hydrophobic interactions between protein 360 
molecules.  361 
 362 
3.3.3 Thermogravimetric analysis (TGA) 363 
Table 2 shows the different (1st ± 4th) thermal events and the dynamic weight loss associated 364 
with those events. In all cases, the first dynamic weight loss observed can be attributed to 365 
desorption of water hydrogen bonded to the polymer structure [28]. SA powder had higher 366 
moisture content (18.24%) than the films (6.52-16.68%) which could be attributed to the drying 367 
process employed when formulating the films. The peak temperature at which the moisture 368 
content within the blank film matrix was lost was significantly lower (45.1°C) than those of 369 
the protein loaded films. This bonded water can be clearly seen in all protein loaded film 370 
temperatures ranging from 53.9°C to 112.2°C. The degradation temperatures decreased for all 371 
the films in comparison to the starting material (SA). This can be attributed to the effect of the 372 
formulation process in changing the physiochemical properties of the starting material due to 373 
interactions between the components of the formulation. SA showed a three stage degradation 374 
process (236.7°C, 257.6°C and 388.7°C) that can be attributed to the presence of carbonaceous 375 
residues [29]. However, GLY only showed one main thermal event above 200°C at a 376 
temperature of 220.4°C which might relate to boiling as observed in DSC, though the 377 
temperatures are different. This shows that the starting materials (SA and GLY) are thermally 378 
stable up to temperatures above 200°C. 379 
 380 
3.4 Mechanical tensile characterization 381 
Table 3A shows that unplasticised films (SA:GLY 1:0) were highly brittle as evidenced by 382 
having the lowest % elongation (1.85 ± 0.19%) and highest values for both elastic modulus and 383 
tensile strength, implying these could cause trauma to newly formed skin cells on a healing 384 
wound [15]. However, addition of GLY caused a general increase in flexibility as evidenced 385 
by the increased % elongation (from 1.85 to 38.84%DQGGHFUHDVHLQERWK<RXQJ¶VPRGXOXV386 
(rigidity) (from 20.77 to 0.40mPa) and tensile strength (brittleness) (from 51.34 to 6.12 387 
N/mm2). This can be attributed to GLY interpolating itself between SA polymer chains 388 
resulting in reduced interaction and the intermolecular cohesive forces between the polymer 389 
chains [30, 31].  390 
 391 
Table 3B shows the variations in tensile profiles based on the type and amount of protein for 392 
the optimized films (SA:GLY 1:2). The % elongation at break reduced from 38.84 ± 0.86% for 393 
blank films to between 23.31 ± 4.04 and 5.46 ± 0.92% depending on the type and amount of 394 
protein loaded. These values are below that considered ideal for wound dressing as it suggests 395 
ORZHUHODVWLFLW\+RZHYHUWKHHODVWLF<RXQJ¶VPRGXOXVDQGWHQVLOHVWUHQgth values showed 396 
the films were not too brittle and this was confirmed during physical handling of the drug 397 
loaded films. Further, the three different protein loaded films possessed different levels of 398 
flexibility with GST-GFP films having the highest flexibility (highest % elongation) as 399 
opposed to GST and GFP loaded films. This could be as a result of GST-GFP being a construct 400 
of both proteins, therefore an increase in molecular weight. 401 
 402 
From the results in Table 3, it can be seen that on the whole, YounJ¶VPRGXOXVGHFUHDVHGZLWK403 
increasing concentrations of proteins with the exception of GFP where the value increased from 404 
0.97 ± 0.40mPa for 3.3mg/g film to 2.14 ± 0.34mPa for 6.6mg/g film but then decreased to 405 
0.88 ± 0.17mPa for the 30.2mg/g film. This suggests that the protein incorporated in the films 406 
improved the films toughness and ability to withstand mechanical pressure whilst maintaining 407 
enough flexibility. Generally, a decrease in tensile strength was observed for most of the 408 
protein loaded films (except GFP 6.6mg/g and GST 3.3mg/g films) in comparison to the blank 409 
films, implying a reduction in film brittleness. This suggests that the proteins possess some 410 
degree of plasticizing effect on the films, thereby imparting flexibility, elasticity and improved 411 
toughness.  412 
 413 
3.5 Scanning electron microscopy (SEM) 414 
Fig. 4 shows that increasing GLY (plasticizer) concentration had an effect on the film 415 
morphology. The unplasticised film showed a clear uniform morphology whilst films prepared 416 
from gels containing SA:GLY 2:1, 4:3, 1:1 showed a rough uneven topography. Furthermore, 417 
it can be seen from Fig. 4 that with further increase in the concentration of GLY in the original 418 
gel (SA:GLY 2:3, 1:2), the topography of the films smoothens out, therefore producing 419 
homogenous uniform films that will be suitable for protein loading. SA film containing GLY 420 
in ratio SA:GLY 1:2, was chosen as being the most uniform of the six formulated films (Fig. 421 
4) and used for protein loading, which confirms the tensile results. 422 
 423 
The proteins (GFP, GST and GST-GFP) had little impact on the film morphology and 424 
topography (Fig. 5) of the optimized films though slight differences could be observed between 425 
GFP, GST and GFP-GST loaded films based on the drug loading, GFP, GST and GST-GFP 426 
(Fig. 5 A, D and G) respectively.  427 
3.6 Hydration and swelling 428 
It can be observed from Fig. 6 that most of the films showed percentage swelling index values 429 
ranging from approximately 650 to 1000% which were not significant (p > 0.05) as evidenced 430 
by the positions of the standard deviation bars. However, two films with higher concentrations 431 
(30.2mg/g) of GST-GFP, and GFP) possessed significantly (p < 0.05) higher percentage 432 
swelling index values compared to the other drug loaded films. The higher percentage swelling 433 
index observed in the higher protein (30.2 mg/g) loaded films could be attributed to the high 434 
protein content attracting water molecules due to its increased solubility. Both blank and 435 
protein loaded films showed high percentage swelling index, indicating a high holding capacity 436 
for wound exudate while still maintaining their structural integrity which can be attributed to 437 
hydrogel properties of SA.  438 
 439 
3.7 In-vitro wound adhesion 440 
The peak adhesive force (PAF) representing maximum force required to separate the films 441 
from the simulated wound surface, the area under the curve (AUC) representing the total work 442 
of adhesion (TWA) and the cohesiveness representing the distance travelled (mm) before 443 
detaching from the simulated wound surface were determined. Fig. 7 showed that the blank 444 
films had the highest cohesiveness and TWA values with the latter indicating the strong 445 
interactions (hydrogen bond formation) between the polymeric chains of SA and the simulated 446 
wound surface. There was no statistically siginficant difference observed in PAF (stickiness) 447 
between the GFP loaded films  and the blank film (p = 0.7132, 0.0610, 0.7703 respectively). 448 
However, there was significant differences observed in TWA between the blank and GFP 449 
loaded films (p = 0.0045, 0.0010, 0.0022 respectively). In addition, GFP loaded films 450 
containing 30.2mg/g, 6.6mg/g of the protein showed no significant difference in cohesiveness 451 
with the blank films (p = 0.0807, 0.1375) while GFP  loaded film containing 3.3mg/g of the 452 
protein was significantly different from the blank film in cohesiveness (p = 0.0211). 453 
 454 
Generally, it was also noted (Fig. 7) that with decrease in protein concentration, an increase in 455 
adhesive strength (TWA and PAF) was observed for all protein loaded films. This could be the 456 
result of higher protein loading (30.2mg/g) impacting on the films, providing less free hydrogen 457 
bonding sites leading to higher hydration as seen in Fig. 7 and less adhesive strength.  458 
3.8 In vitro protein dissolution and release studies 459 
Fig. 8 shows that the film dressings appeared to show rapid initial release of protein followed 460 
by constant release over a longer period. However, GST loaded dressing showed higher total 461 
cumulative release (90%) than GFP (78%) and GST-GFP (67%) dressings. It can also be seen 462 
that 78%, 70% and 64% release from GST, GFP and GST-GFP loaded dressing films 463 
respectively occurred within the first 2 hours (Fig. 8 inset). According to Table 4, GST-GFP 464 
protein release was proportional to time which is a non-concentration dependent mechanism 465 
involving the swelling and dissolution of the polymeric matrix (zero order mechanism). GFP 466 
released was proportional to the square root of time (t1/2) indicating a Fickian diffusion 467 
controlled mechanism. GST however, had identical R2 values for both Higuchi and zero order 468 
mechanisms. Therefore, GST release data was further evaluated using the Korsmeyer-Peppas 469 
equation and the diffusional exponent (n) was determined to be less than 0.5 (n < 0.5) indicating 470 
a quasi-Fickian diffusion mechanism [32].  471 
 472 
3.9 Structural stability of model proteins by far-UV CD spectroscopy 473 
Fig. 9A, B and C show the far-UV spectra of GST-GFP, GST and GFP in their native state 474 
(control) and after release from the SA film dressings (post-formulation). The ratios of the 475 
mean residue ellipticity were calculated as previously described. The two maxima bands 476 
observed at 209 and 222nm [33, 34] were respectively assigned WRWKHĮ-KHOLFDODQGȕ-sheet 477 
structures of GST-GFP (Fig. 9A) and GST (Fig. 9B). GST-GFP and GST released from SA 478 
films and the native protein VKRZHGVLPLODUPHDQUHVLGXHHOOLSWLFLW\UDWLRVș209 ș222) of 1.0 479 
(GST-GFP) and 1.2 (GST). Fig. 9C (GFP) shows tKDW*)3SUHGRPLQDQWO\FRQVLVWHGRIȕ-sheet 480 
structures and has also been reported by Visser and co-workers [35]. The similarity in the far-481 
UV spectra (Fig. 9A, B and C) and the mean residue ellipticity ratios obtained (GST-GFP and 482 
GST) pre and post-formulation confirmed the conformational stability of all three proteins 483 
within the film dressings. 484 
 485 
4. Discussion 486 
The model proteins (GST, GFP and GST-GFP) were chosen because they could be readily 487 
cultured using bacteria (in house), isolated and characterized with various physical and bio- 488 
analytical techniques. This was necessary due to the large amounts of proteins needed during 489 
the formulation development and optimization process. Coomassie staining was used to detect 490 
the molecular weights of the recombinant GST-GFP protein and BSA at concentrations 5µg 491 
and 75µg respectively. BSA was used as a control to validate that the gel was working 492 
optimally as its molecular weight is constant (~66kDa) and confirmed that the proteins were 493 
separated according to molecular weight. 494 
 495 
All the materials used were generally considered as safe (GRAS). Dextran (synthesized by 496 
Leuconostoc bacteria) is a complex polysaccharide made of glucose molecules [36] and was 497 
used as a negative control due to its low toxicity. On the other hand, PEI is a commercially 498 
available polyamine [37] and a gene carrier with reasonable transfection efficiency and high 499 
cytotoxicity. It is reported in literature [38, 39] that SA is generally regarded as non-toxic and 500 
used in oral formulations as well as food substances, however, none of these literature 501 
references show a clear profile on the absence of toxicity of SA against epithelial cells. In the 502 
current study, safe model proteins have been used but this test can also be used in 503 
determining toxicity levels of growth factors (which play an important role during wound 504 
healing) on live mammalian epithelial cells. This will help to investigate the effect of 505 
different dose levels of growth factors delivered directly to wound sites, to avoid excessive 506 
proliferation of cells and thus, preventing the risk of triggering cancerous cells.  507 
 508 
The stability of the proteins under various conditions were investigated using various thermal 509 
analysis techniques. Though two related scanning calorimetry techniques (HSDSC and DSC) 510 
were used, this was necessary since the HSDSC is effective for analyzing sensitive biological 511 
samples such as proteins as well as liquid samples (solutions) whilst DSC is generally more 512 
useful for samples in the solid state and small molecules. The HSDSC data shows that the 513 
GFP is a more thermally stable protein than GST. Therefore high temperatures of up to 70°C 514 
(14°C less than the Tmax of GFP at pH 7.5) and temperatures of up to 45°C (14°C less than 515 
the Tmax of GST at pH 7.5) can be employed during formulation or processing. The ratio 516 
Tm/Tmax is an indicator of thermal stability and generally, the higher the Tm/Tmax, the more 517 
thermodynamically stable the protein [25]. Generally, the variations observed in the HSDSC 518 
can be attributed to the influence of pH, causing aggregation and / or degradation of the 519 
proteins within the buffers at the various pH values especially at 6.0 and 10.0.  520 
 521 
DSC was used to determine possible interactions between the various film components as well 522 
as stability of the proteins within the film matrix. The exothermic peak observed in SA was not 523 
seen in the formulated gels or in the films possibly due to interactions between the formulation 524 
components, and molecular dispersion of the protein drugs within the formulation [40]. This 525 
observation is similar to that previously reported in another study [41] where degradation 526 
exotherm of pure SA was absent in corresponding drug loaded alginate beads but rather, an 527 
endotherm, corresponding to the interaction of alginate with calcium ions naturally present in 528 
SA was observed. The differences observed between the DSC profiles could be an indication 529 
of fewer interactions between the GST proteins (3.3 and 30.2mg/g) and the polymer network 530 
and further evidenced by the closeness of the dehydration peak temperatures and enthalpies for 531 
GST (3.3 and 30.2mg/g) loaded and blank films. 532 
 533 
The TGA results demonstrate that the different films generally possessed similar water content. 534 
The higher temperature of complete water loss in protein loaded films could be related to 535 
intermolecular forces such as hydrogen-bonds, van der Waals force and hydrophobic 536 
interactions between the proteins, and the starting materials within the film matrix, resulting in 537 
well-ordered bound water compared to the free water in the blank films. It is reported that water 538 
molecules play a vital role in maintaining the structure, dynamics, stability and function of 539 
biological molecules as they are responsible for packing and stabilization of the protein 540 
structure particularly in forming H-bond networks and screening of electrostatic interactions 541 
[42]. Papoian et al., reported a substantial improvement in protein structure prediction by 542 
adding a water-based potential to a well-known Hamiltonian for protein structure prediction 543 
[43]. Wetting the Hamiltonian improved the predicted structures, particularly of large proteins 544 
(>115 amino acid residues) through long range interactions between charged or polar groups 545 
facilitated by water molecules. However, bulk free water allows for rotational freedom within 546 
proteins, causing flexibility and enzymatic activities, thus, increasing reactivity and therefore 547 
an increase in entropy (disorderliness) in the protein [44]. 548 
 549 
Overall, the thermal analysis data shows the impact of the dressing formulation on the 550 
properties of the protein and vice versa in terms of stability and mechanical integrity 551 
respectively. At the temperature of 45°C and 40°C used for gel preparation and oven drying 552 
respectively, it is feasible to undertake the formulation development of alginate based 553 
dressing incorporating therapeutically relevant macromolecules without causing degradation. 554 
However, this will need to be confirmed with actual therapeutic proteins such as growth 555 
factors.  556 
 557 
Texture analysis was used to measure the tensile properties; first to determine the effect of 558 
GLY concentrations the film behavior and the resulting data used to select the most appropriate 559 
formulation for protein loading and determine effect of drug concentration on the film tensile 560 
properties. Generally for film dressings, a balance between toughness (rigidity) and elasticity 561 
(flexibility) is required [15]. Tough films allow ease of handling without being sticky and 562 
folding up, whilst being flexible enough to allow easy application to the wound site and enable 563 
applications to difficult areas of the body such as parts around the joints and under the foot. 564 
This is normally achieved by having a % elongation value between 30±60% [15, 40] and this 565 
was only satisfied by the SA:GLY 1:2 films with % elongation value of 38.84% and were 566 
therefore selected for drug loading and further testing.  567 
 568 
The rough and uneven topography (SEM) observed in films prepared from gels containing 569 
SA:GLY 2:1, 4:3, 1:1, can be detrimental to protein loading as content uniformity cannot be 570 
achieved in these films due to their rough topography. Rather, loaded drugs could be trapped 571 
and non-uniformly dispersed across the rough surfaces of these films, thereby hindering dosage 572 
accuracy as well as consistent drug release. 573 
 574 
For effective wound healing, an ideal dressings is expected to be able to absorb large quantities 575 
of exudate whilst maintaining its structural integrity over long periods as well as keeping the 576 
wound environment moist to facilitate wound healing. SA dressings are good absorbents that 577 
gradually form hydrophilic gels upon contact with wound exudate, thereby promoting a moist 578 
wound environment, the formation of granulation tissue and wound healing. It is reported [2] 579 
that moderate to high exuding wounds produce approximately 3-5 mL of wound exudate / 580 
10 cm2 in 24 hours. Therefore, 0.6-1.0 mL wound exudate is produced per 2 cm2 in 24 hours. 581 
In this study, films (blank and protein loaded) absorbed 625-1732% of SWF which is an 582 
indication that these dressings can absorb high amounts of wound exudate and can be used for 583 
moderate to high exuding wounds. It is reported that excessive hydrations as seen in the higher 584 
protein loaded films (30.2mg/g) (Fig. 6) can lead to reduced bioadhesion due to the formation 585 
of a slippery surface between the films and the simulated wound surface [45]. Adhesivity in 586 
wound healing is important as wound dressing should be self-adhesive with the wound so as 587 
not to fall off but be easily removed and painless [7]. 588 
 589 
Furthermore, the higher swelling properties of the 30.2mg/g protein loaded films could have 590 
led to a reduction in flexibility, which is important as it determines the extent of entanglement 591 
and enhances interpenetration between polymer (SA) and the simulated wound surface. The 592 
comparison of the swelling and bio-adhesive properties of the different formulations was used 593 
to determine the film dressing with the ideal functional properties. Based on the observed 594 
profiles, the 6.6mg / g protein loaded film was concluded to be the dressing with the optimum 595 
swelling and bio-adhesive properties and was subsequently used for in vitro drug (protein) 596 
dissolution studies. 597 
 598 
The differences observed in the overall % cumulative release might relate to the relative 599 
difference in solubility between the three proteins as well as their interactions with the polymer 600 
(SA). In addition, initial burst release may be attributed to the dissolution and rapid release of 601 
the surface associated protein molecules coupled with initial hydration and swelling above 60% 602 
in the first hour. Generally for a polymeric matrix such as solvent cast films, swelling, and 603 
solute diffusion and matrix degradation are proposed as the main driving forces responsible for 604 
drug release [46, 47]. Overall, it can be seen (Fig. 8) that after the initial burst release, the 605 
protein release was sustained over a period of 72 hours for all three protein loaded films. This 606 
second phase could be attributed to diffusion from the hydrated and swollen gel. This will help 607 
prevent frequent changing of the dressings so as not to disrupt newly formed skin tissues, 608 
reduce side effects through extended dosing as well as for patient compliance [46].  609 
 610 
5 Conclusions 611 
 Adhesive SA film dressings were successfully developed as potential protein delivery systems 612 
for wound healing. The blank (SA:GLY 1:2) film was determined to be the optimized 613 
formulation for protein drug loading and further development. The absence of free water 614 
molecules within the film matrix was advantageous to ensure protein stability in the film and 615 
was confirmed by CD. Overall, the formulations containing 6.6mg of protein per gram of film 616 
exhibited optimum hydration and adhesive properties required for wound dressings. Further, 617 
protein release from the dressing was sustained over 72 hours which is expected to allow good 618 
bioavailability of the model protein drug at the site of action. 619 
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Figure Legends 748 
Fig. 1. (a) Developed X-ray film showing detection of affinity purified GFP by western 749 
immunoblotting (anti body dilutions, 1:3000, exposure time; 10 seconds); (b) developed X-ray 750 
film showing detection of affinity purified GST by western immunoblotting (anti body 751 
dilutions, 1:3000, exposure time; 10 seconds) and (c) developed X-ray film showing detection 752 
of affinity purified recombinant GST-GFP by western immunoblotting (anti body dilutions, 753 
1:2000, exposure time; 1 second). 754 
 755 
Fig. 2. Toxicity profiles of SA (starting material), dextran and PEI used as negative and positive 756 
controls respectively (n=6 ± SD), the three model protein drugs (GST, GFP and GST-GFP) 757 
(n=6 ± SD) against vero cell lines after 72 hours exposure time. 758 
 759 
Fig. 3. DSC thermograms of (A) GLY, (B) SA and (C) the blank and protein loaded films. 760 
 761 
Fig. 4. SEM micrographs (x50 magnification) showing the effect of increasing GLY 762 
concentrations on film topography and morphology. 763 
 764 
Fig. 5. SEM micrographs (x200 magnification) showing the effect of protein loading on the 765 
surface morphological properties of the plasticized SA: GLY (1:2) films containing [GFP (A-766 
C), GST, (D-F) and GST-GFP (G-I) loaded film from high (left) to low (right) concentrations 767 
(30.2, 6.6 and 3.3mg/g) respectively. 768 
 769 
Fig. 6. Hydration and swelling profiles of the blank and protein loaded film dressings (n=3 ± 770 
SD). 771 
 772 
Fig. 7. In vitro adhesive profiles for blank and drug loaded films (n=4 ± SD) 773 
 774 
Fig. 8. Dissolution profiles of protein (6.6mg/g) loaded film dressings (n = 4, ± SD) 775 
 776 
Fig. 9. CD spectra of (A), GST-GFP, (B), GST and (C), GFP in native state and post release 777 
from film dressing (0.96mg/mL solution used). 778 
 779 
 780 
 781 
 782 
 783 
 784 
 785 
 786 
 787 
 788 
 789 
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 791 
 792 
 793 
 794 
 795 
 796 
 797 
TABLES 798 
Table 1  799 
Thermal stability of proteins (GST-GFP, GST and GFP) as a function of scan rate, 800 
concentration and pH using HSDSC. 801 
Protein Scan rate 
(oC/min) 
Concentration 
(mg/mL) 
ǻ+ 
(KJ/mol) 
 
Tmax (oC) 
 
pH 
GST 0.5 5.0 73.25 56.27 7.5 
GST 1.0 5.0 91.35 57.77 7.5 
GST 2.0 5.0 66.14 59.09 7.5 
GST 0.5 2.5 71.97 55.55 7.5 
GST 1.0 2.5 71.77 57.32 7.5 
GST 2.0 2.5 88.67 59.19 7.5 
GST 0.5 1.0 96.47 56.30 7.5 
GST 1.0 1.0 102.14 57.21 7.5 
GST 2.0 1.0 126.87 60.70 7.5 
GST 1.0 1.0 6.27 55.32 6.0 
GST 1.0 1.0 82.30 56.96 8.0 
GST 1.0 1.0 53.71 51.69 10.0 
GFP 0.5 5.0 88.24 81.58 7.5 
GFP 1.0 5.0 67.61 83.03 7.5 
GFP 2.0 5.0 90.62 84.32 7.5 
GFP 0.5 2.5 90.99 81.57 7.5 
GFP 1.0 2.5 69.89 83.05 7.5 
GFP 2.0 2.5 95.71 84.46 7.5 
GFP 0.5 1.0 95.15   82.14 7.5 
GFP 1.0 1.0 68.35   83.36 7.5 
GFP 2.0 1.0 93.75 84.49 7.5 
GFP 1.0 1.0 43.06 81.22 6.0 
GFP 1.0 1.0 78.48 82.99 8.0 
GFP 1.0 1.0 51.71 76.83 10.0 
 
  GST GFP GST GFP  
GST-GFP 0.5 5.0 86.18 112.61 55.44 81.11 7.5 
GST-GFP 1.0 5.0 91.55 125.87 56.51 82.49 7.5 
GST-GFP 2.0 5.0 72.69 104.63 57.96 84.02 7.5 
GST-GFP 0.5 2.5 46.96 61.08 54.44 81.23 7.5 
GST-GFP 1.0 2.5 95.37 127.35 56.08 82.65 7.5 
GST-GFP 2.0 2.5 67.80 91.54 57.52 84.02 7.5 
GST-GFP 0.5 1.0 66.98 112.14 54.10 81.12 7.5 
GST-GFP 1.0 1.0 72.43 78.94 55.49 83.19 7.5 
GST-GFP 2.0 1.0 79.86 105.12 57.24 84.08 7.5 
GST-GFP 1.0 1.0 60.22 67.45 55.17 79.86 6.0 
GST-GFP 1.0 1.0 50.06 207.21 55.34 70.18 8.0 
GST-GFP 1.0 1.0 70.29 131.12 52.81 76.15 10.0 
 802 
 803 
 804 
 805 
 806 
 807 
 808 
 809 
 810 
 811 
 812 
 813 
 814 
 815 
 816 
 817 
 818 
Table 2 Dynamic weight loss (%) and degradation temperatures (°C) of samples (n=3, mean ± SD). The 1st represents water loss 819 
the remaining refer to weight loss due to other events, mainly degradation. 820 
821 
Samples  Dynamic weight loss (%) Degradation temperatures (°C) 
1st  
(water loss) 
2nd 3rd 4th Total  1st 2nd 3rd 4th 
SA 18.2±0.7 36.3±0.5 10.3±0.9 - 64.9 ± 0.3 60.4±2.1 236.7±0.1 257.6±5.6 388.73±5.6 
GLY 16.1±0.1 84.0±0.1 - - 100.1± 0.1 79.7±1.4 220.4±2.0 - - 
BLK films 13.6±0.2 57.1±0.4 5.0±0.2 - 75.8±0.0 45.1±0.0 212.3±0.0 557.7±0.0 - 
GFP films 
(30.2mg/g) 
9.5±0.0 11.4±1.2 43.1±1.0 3.8±0.7 68.2±0.1 112.2±0.0 182.9±0.0 211.9±0.5 - 
GFP films 
(6.6mg/g) 
6.5±0.0 15.1±0.2 44.6±0.2 2.8±0.0 68.9±0.0 109.3±0.0 180.5±0.0 213.6±0.0 - 
GFP films 
(3.3mg/g) 
5.5±0.1 16.2±0.8 45.1±0.1 3.7±0.6 70.6±0.0 66.5±0.0 187.0±0.5 213.4±0.5 540.4±0.0 
GST films 
(30.2mg/g) 
16.7±0.1 49.9±0.0 - - 66.6±0.2 59.8±0.01 209.4±0.1 - - 
GST films 
(6.6mg/g) 
13.8±0.5 52.8±0.5 2.8±0.3 - 70.8±1.7 65.1±0.01 204.0±1.2 563.6±0.5 - 
GST films 
(3.3mg/g) 
14.7±0.5 50.8±0.0 3.1±0.6 2.3±0.9 70.9±0.8 53.9±2.3 197.7±1.2 370.9±0.5 - 
GST-GFP 
films 
(3.3mg/g) 
15.1±0.2 54.5±0.2 1.5±0.2 - 71.4±0.3 65.2±0.5 210.2±0.5 - - 
GST-GFP 
films 
(6.6mg/g) 
11.9±0.2 16.7±0.6 42.4±0.5 3.4±0.3 74.5±0.3 62.2±0.5 182.6±2.6 208.6±0.5 568.6±1.6 
GST-GFP  
films 
(3.3mg/g) 
12.6±0.0 58.4±0.4 3.0±0.0  
- 
74.1±0.3 60.6±0.5 210.7±0.0 567.4±1.0 - 
Table 3 822 
(A) The effect of increasing plasticizer (GLY) on the mechanical (tensile) properties of blank 823 
SA films (mean ± SD, n=3); (B) Mechanical (tensile) properties, % elongation at break, 824 
<RXQJ¶VPRGXOXVDQGWHQVLOHVWUHQJWKRIRSWLPL]HGILOPV(SA:GLY 1:2) loaded with proteins 825 
at different concentrations [mean ± SD, (n = 3)]. 826 
(A) 827 
Films - Blank % elongation at 
break (mean ± SD) 
<RXQJ¶VPRGXOXV
(mPa) (mean ± SD) 
Tensile strength 
(N/mm2) (mean ± SD) 
SA:GLY (1:0) 1.85 ± 0.19 20.77 ± 4.19 51.34 ± 6.76 
SA:GLY (2:1) 5.37 ± 0.96 5.43 ± 2.00 21.26 ± 0.25 
SA:GLY (4:3) 19.70 ± 1.77 3.21 ± 0.72 12.39 ± 0.43 
SA:GLY (1:1) 7.43 ± 0.87 3.12 ± 2.62 9.04 ± 0.59 
SA:GLY (2:3) 10.10 ± 2.12 0.80 ± 0.34 3.81 ± 0.51 
SA:GLY (1:2) 38.84 ± 0.86 0.40 ± 0.08 6.12 ± 0.11 
(B)  828 
Films ± Drug loaded % elongation at 
break  
(mean ± SD) 
<RXQJ¶VPRGXOXV
(mPa)  
(mean ± SD) 
Tensile strength 
(N/mm2)  
(mean ± SD) 
GST films (30.2mg/g) 11.76 ± 2.55 0.42 ± 0.14 4.07 ± 1.19 
GST films (6.6mg/g) 5.46 ± 0.92 0.49 ± 0.13 2.56 ± 0.52 
GST films (3.3mg/g) 6.20 ± 1.04 2.44 ± 0.35 6.36 ± 1.82 
GST-GFP films (30.2mg/g) 20.74 ± 3.25 0.79 ± 0.18 5.04 ± 0.88 
GST-GFP films (6.6mg/g) 23.38 ± 7.61 0.54 ± 0.07 4.77 ± 0.70 
GST-GFP films (3.3mg/g) 19.04 ± 2.46 0.87 ± 0.21 4.50 ± 0.43 
GFP films (30.2mg/g) 9.33 ± 0.66 0.88 ± 0.17 3.77 ± 0.87 
GFP films (6.6mg/g) 7.78 ± 1.86 2.14 ± 0.34 6.16 ± 1.32 
GFP films (3.3mg/g) 23.31 ± 4.04 0.97 ± 0.40 5.05 ± 0.33 
829 
37 
 
Table 4 Release parameters obtained from fitting the dissolution data into different kinetic 
equations for the protein loaded film dressings 
 
Protein  
loaded  
films 
Zero order First order Higuchi Korsmeyer-Peppas 
K0          
(% min-1)
 
R2 K1  
(min-1) 
R2 KH            
(% min-1/2) 
R2 KP             
 
(% min-n) 
n R2 
GST 
6.6mg/g 
0.242 0.906 -0.013 0.904 2.031 0.906 1.340 0.057 0.909 
GFP  
6.6mg/g 
0.010 0.960 -0.001 0.977 0.223 0.986 1.330 0.016 0.986 
GST-
GFP 
6.6mg/g 
0.061 0.963 -0.002 0.961 0.615 0.922 1.021 0.020 0.922 
K0, K1, KH, KP are the release rate constant for zero order, first order, Higuchi and Korsmeyer -Peppas 
kinetic models respectively,
 
n is the release exponent and R2 is the correlation coefficient. 
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APPENDIX - SUPPLEMENTARY DATA 
A1 High sensitivity differential scanning calorimetry (HSDSC) 
Generally, the results show that in all three proteins, an increase in scan rate from 0.5 to 
2.0°C/minute increased the Tmax at pH 7.5 for the same protein concentration. From Table 1, it 
can also be seen that the optimum pH for the three proteins was 7.5 due to the higher Tmax 
observed when compared to that of the other pH values (6.0, 8.0 and 10.0). Further, Table 1 
also shows that the optimum pH for the three proteins was 7.5 due to the higher Tmax observed 
when compared to that of the other pH values (6.0, 8.0 and 10.0). Comparing the Tmax of the 
individual proteins (GST, GFP) to the Tmax of the proteins within the construct (GST-GFP) at 
1mg/mL and pH 7.5, it can be seen (Table 1) that GST was thermally more stable on its own 
than in the presence of GFP in the construct protein (GST-GFP) at all three scan rates (0.5, 1.0 
and 2.0°C / minute). However, the Tmax for GFP alone and within the construct were similar at 
scan rates (1 and 2°C/minute) and differing by about 1.0°C at a scan rate 0.5°C/minute. 
Therefore, it can be concluded that GFP influenced the thermal stability of GST.  
 
(QWKDOS\FKDQJHǻ+IOXFWXDWHGZLWKVFDQUDWHIRUDOOWKUHHSURWHLQVZKLFKLQGLFDWHVWKDWWKH
rate of scanning influences the thermal denaturation process of the three proteins. 
&RQFHQWUDWLRQDOVRLQIOXHQFHGǻ+IRUDOOWKUHHSURWHLQVWKRXJKWKHUHZDVQRGLUHFWFRUUHODWLRQ
However, concentration did not influence the Tmax significantly and therefore a concentration 
of 1mg/mL was used for all three proteins to evaluate the effect of pH on the proteins thermal 
stability.  
 
From Table 1, it can be seen that the optimum pH for the three proteins was 7.5 due to the 
higher Tmax observed when compared to that of the other pH values (6.0, 8.0 and 10.0). For 
example, in the case of GST, the Tmax at the different pHs (7.5, 6.0, 8.0 and 10.0), decreased 
50 
 
from 57.21°C (pH 7.5), 56.96°C (pH 8.0), 55.32°C (pH 6.0) to 51.69°C for pH 10.0. In 
DGGLWLRQǻ+GHFUHDVHGIURPN-PRO, 53.71 kJ/mol and 6.27 N-PROIRUS+¶V
8.0, 10.0 and 6.0) respectively, significantly reducing the enthalpy of the reaction. Similar 
results were also observed for GFP. However, for the construct protein (GST-GFP), the 
differences in Tmax between pHs were not as high compared to the individual proteins (GST 
and GFP). The Tmax ranged from 55.49°C, 55.34°C, 55.17°C for pH 7.5, 8.0, 6.0 respectively 
with about 3°C difference for pH 10.0 (52.81 kJ/mol). However, the difference in ǻ+ZDV
higher for all four pH values; 7.5 (72.43 kJ/mol), 10.0 (70.29 kJ/mol), 6.0 (60.22 kJ/mol) and 
8.0 (50.06 kJ/mol). For GFP within the construct protein (GST-GFP), Tmax values observed 
were 83.19°C, 79.86°C, 76.15°C and 70.18°C, at pH values of 7.5, 6.0, 10.0 and 8.0 
respectively. Comparing the Tmax of the individual proteins (GST, GFP) to the Tmax of the 
proteins within the construct (GST-GFP) at 1mg/mL and pH 7.5, it can be seen (Table 1) that 
GST was thermally more stable on its own than in the presence of GFP in the construct protein 
(GST-GFP) at all three scan rates (0.5, 1.0 and 2.0°C / minute) with the difference in Tmax 
between 2.0±3.0°C. However, the Tmax for GFP alone and within the construct were similar at 
scan rates (1 and 2°C/minute) and differing by about 1.0°C at a scan rate 0.5°C/minute. 
Therefore, it can be concluded that GFP influenced the thermal stability of GST.  
 
A2 Differential scanning calorimetry (DSC) 
The peaks around 100oC are associated with protein decomposition, however, at this 
temperature, all three protein would have denatured from their native state. This suggests that 
the peak at 100oC could be decomposition of denatured proteins but this may require further 
investigation. Peaks at around 0oC are due to thermal melting of the proteins as the temperature 
increased. The peak at approximately -20oC can be attributed to phase transition of the proteins 
in the crystal state prior to melt at 0oC. Both GST and GFP showed this phase transition at -
51 
 
22.89oC and -22.09 respectively. However, GST-GFP produced two peaks at this phase that 
can be attributed to the presence of both GST and GFP in the recombinant GST-GFP.  
 
 
